[go: up one dir, main page]

AR036728A1 - Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico - Google Patents

Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico

Info

Publication number
AR036728A1
AR036728A1 ARP020103740A ARP020103740A AR036728A1 AR 036728 A1 AR036728 A1 AR 036728A1 AR P020103740 A ARP020103740 A AR P020103740A AR P020103740 A ARP020103740 A AR P020103740A AR 036728 A1 AR036728 A1 AR 036728A1
Authority
AR
Argentina
Prior art keywords
hepatitis
alpha
virus
infection caused
ifn
Prior art date
Application number
ARP020103740A
Other languages
English (en)
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AR036728A1 publication Critical patent/AR036728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas para tratar la infección causada por el virus de la hepatitis. Las composiciones en general involucran un agente antiviral en un régimen de dosificación que logra un perfil de concentración en suero multifásico del agente antiviral. El régimen de dosificación incluye eventos de dosificación que son menos frecuentes que con las terapias para la hepatitis actualmente disponibles. El perfil de concentración en suero multifásico del agente antiviral que es logrado utilizando las composiciones, efectúa una rápida caída inicial en el título viral, seguido por una disminución adicional en el título viral en el tiempo, para lograr una respuesta viral sostenida. Reivindicación 1: Una composición farmacéutica destinada para tratar la infección causada por el virus de la hepatitis C en un individuo que comprende interferon-alfa (IFN-alfa) en una cantidad efectiva para lograr una primera concentración en suero de IFN-alfa que es al menos aproximadamente 80% de la dosis máxima tolerada (MTD)dentro de un primer período de tiempo de aproximadamente 24 a 48 horas, seguido por una segunda concentración de IFN-alfa que es aproximadamente 50% o menos de la MTD, segunda concentración que se mantiene durante un segundo período de tiempo de por lo menos siete días.
ARP020103740A 2001-10-05 2002-10-03 Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico AR036728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32774401P 2001-10-05 2001-10-05

Publications (1)

Publication Number Publication Date
AR036728A1 true AR036728A1 (es) 2004-09-29

Family

ID=23277854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103740A AR036728A1 (es) 2001-10-05 2002-10-03 Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico

Country Status (15)

Country Link
US (2) US20050063949A1 (es)
EP (1) EP1450838A4 (es)
JP (1) JP2005508943A (es)
KR (1) KR20050030886A (es)
CN (1) CN1738635A (es)
AR (1) AR036728A1 (es)
BR (1) BR0213103A (es)
CA (1) CA2460690A1 (es)
HU (1) HUP0401818A2 (es)
IL (1) IL160965A0 (es)
MX (1) MXPA04003238A (es)
NO (1) NO20041814L (es)
PL (1) PL369870A1 (es)
WO (1) WO2003030923A1 (es)
ZA (1) ZA200402236B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225870B2 (en) 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2286359A2 (en) * 2008-03-27 2011-02-23 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
US20090246171A1 (en) * 2008-03-27 2009-10-01 Van Antwerp William P Automatic system for dose control in treating hepatitis c using infusion pumps
JP5599778B2 (ja) 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
EP2459211A1 (en) * 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1023901A4 (en) * 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd MEDICINES FOR HEPATITIS C AND THE USE THEREOF
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry

Also Published As

Publication number Publication date
US20050063949A1 (en) 2005-03-24
CN1738635A (zh) 2006-02-22
ZA200402236B (en) 2005-03-22
JP2005508943A (ja) 2005-04-07
WO2003030923A1 (en) 2003-04-17
MXPA04003238A (es) 2004-07-08
EP1450838A4 (en) 2005-09-28
PL369870A1 (en) 2005-05-02
BR0213103A (pt) 2004-09-21
HUP0401818A2 (hu) 2004-11-29
NO20041814L (no) 2004-06-11
CA2460690A1 (en) 2003-04-17
US20090196853A1 (en) 2009-08-06
KR20050030886A (ko) 2005-03-31
EP1450838A1 (en) 2004-09-01
IL160965A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
AR036728A1 (es) Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico
HUP0003384A2 (hu) Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
CN1094642A (zh) 治疗组合物
CZ286827B6 (cs) Přípravek pro léčení savců infikovaných virem hepatitidy C
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
RU2242242C2 (ru) Препаративная форма стабильного водного раствора интерферона, способ ее приготовления и использования
USRE40882E1 (en) Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant
TR200102024T2 (tr) Yeni tedavi.
Jain et al. Trial of ribavirin for the treatment of HBsAg positive chronic liver disease
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
FR2694693B1 (fr) Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
WO2004033479A3 (en) Retroyclins: antiviral and antimicrobial peptides
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
US11724077B2 (en) Therapeutic swabs for treating upper respiratory infections
CA1336491C (en) Antiviral pharmaceutical composition
PT886527E (pt) Composicao farmaceutica que incorpora o interferao alfa humano natural
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
SUN et al. Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats
RU2833350C1 (ru) Интраназальное противовирусное средство
JPH06298665A (ja) 抗ウイルス剤
US8217014B2 (en) Pharmaceutical composition for treatment of blood clotting disorder
GADZIK et al. Inhibition of virus-induced murine diabetes by an interferon inducer
US20030031647A1 (en) IFN-alpha and amantadine for treating hepatitis C

Legal Events

Date Code Title Description
FB Suspension of granting procedure